Executive Summary / Key Takeaways

• Abeona Therapeutics has successfully transitioned to a commercial-stage company with the recent FDA approval of ZEVASKYN™ (prademagene zamikeracel), the first and only autologous cell-based gene therapy for RDEB wounds, marking a pivotal moment for the company and patients.
• The sale of the Rare Pediatric Disease Priority Review Voucher for $155 million significantly strengthens Abeona's balance sheet, providing over two years of funding and eliminating the need for additional capital to reach projected ZEVASKYN-driven profitability in early 2026.
• The commercial launch of ZEVASKYN is underway through a focused network of Qualified Treatment Centers (QTCs), with the first site activated and patient treatments expected to begin in Q3 2025, supported by a strategically ramping manufacturing capacity and proactive market access efforts.
• ZEVASKYN's differentiated profile, offering durable wound healing and pain reduction with a single application for large, chronic RDEB wounds, positions it uniquely within the competitive landscape, complementing existing therapies and addressing a high unmet need.
• While initial financial results reflect ongoing R&D and launch preparation costs, the outlook is positive, with management guiding towards treating 10-14 patients in 2025 and anticipating positive EPS in 2026, supported by the strong cash position and commercial ramp.

Abeona Therapeutics: From Clinical Promise to Commercial Reality

Abeona Therapeutics stands at a transformative juncture, having successfully navigated the complex path from a clinical-stage biotechnology company to a commercial entity with the recent U.S. Food and Drug Administration (FDA) approval of its lead asset, ZEVASKYN (prademagene zamikeracel). This milestone, achieved on April 28, 2025, positions Abeona squarely in the specialized field of cell and gene therapies for life-threatening rare diseases, specifically addressing the severe and debilitating genetic skin condition, recessive dystrophic epidermolysis bullosa (RDEB).

The company's journey has been marked by strategic licensing agreements and dedicated research, particularly focused on developing EB-101 (now ZEVASKYN), an autologous cell-based gene therapy. This involves taking a patient's own skin cells, genetically modifying them to produce functional Type VII collagen (COL7A1) using a retroviral vector, and then growing these cells into sheets for surgical application to RDEB wounds. This approach is fundamentally different from topical or systemic treatments and forms the core of Abeona's technological differentiation in the RDEB space.

In the competitive landscape for RDEB treatments, ZEVASKYN enters a market with existing therapies like Krystal Biotech's (KRYS) Vyjuvek. However, ZEVASKYN's technology offers distinct advantages. Unlike Vyjuvek, which is a topical gene therapy requiring ongoing weekly applications, ZEVASKYN is designed as a single-application, cell-based therapy for treating large, chronic wounds. Clinical data from the pivotal Phase III VIITAL study and earlier Phase I/IIa trials have demonstrated compelling durability, with some wounds remaining healed for years following a single treatment. This is hypothesized to be due to the persistence of gene-modified progenitor cells within the applied sheets, providing long-term expression of functional collagen 7. This quantifiable benefit – durable healing and pain reduction from a single procedure – is a critical differentiator, particularly for patients suffering from extensive, non-healing wounds that significantly impact their quality of life and are prone to infection and squamous cell carcinoma. While other gene therapy companies like Bluebird Bio (BLUE), Sarepta Therapeutics (SRPT), and CRISPR Therapeutics (CRSP) operate in the broader rare disease gene therapy space, Abeona's focus on RDEB with an autologous cell-based approach carves out a specific niche. Management views ZEVASKYN as complementary to existing therapies, suggesting that physicians may utilize different treatments based on wound type and patient needs, positioning ZEVASKYN as the "big guns" for large, painful, chronic wounds requiring instantaneous closure and durable healing.

Beyond ZEVASKYN, Abeona is also leveraging its technological expertise in adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases, utilizing novel AIM capsids licensed from UNC. These capsids are being evaluated to improve tropism profiles, aiming for enhanced delivery to target tissues. Preclinical programs for Stargardt disease (ABO-504), X-linked retinoschisis (ABO-503), and autosomal dominant optic atrophy (ABO-505) are advancing, with pre-IND meetings completed and plans to move at least one asset into human trials in the second half of 2026. While these programs are earlier stage and manufacturing is outsourced to CDMOs, they represent future growth drivers and demonstrate the company's broader gene therapy capabilities.

Financially, Abeona's history has been characterized by significant R&D investment and operating losses, a common trajectory for biopharmaceutical companies in the development phase. For the three months ended March 31, 2025, the company reported a net loss of $12.0 million, an improvement from the $31.6 million loss in the same period of 2024. This change was significantly influenced by the non-cash gain from the change in fair value of warrant and derivative liabilities ($7.2 million gain in Q1 2025 vs. $17.3 million loss in Q1 2024), driven by stock price fluctuations. Operating expenses increased year-over-year, with R&D rising by 38% to $9.9 million and G&A increasing by 37% to $9.8 million in Q1 2025. These increases reflect the strategic investments in manufacturing scale-up and increased headcount necessary to prepare for the ZEVASKYN commercial launch.

Interest income saw a notable increase, rising to $1.3 million in Q1 2025 from $0.8 million in Q1 2024, due to higher average short-term investment balances. Despite the reduced net loss, the company continues to incur negative cash flows from operations, with $18.4 million used in operating activities in Q1 2025, compared to $14.5 million in Q1 2024. This underscores the critical need for ZEVASKYN to generate substantial revenue to achieve profitability and positive cash flow.

Abeona's liquidity position has been dramatically transformed by recent events. As of March 31, 2025, the company held $84.5 million in cash, cash equivalents, restricted cash, and short-term investments. Subsequent to the quarter end, the company further bolstered its cash position with $10.5 million in net proceeds from its ATM facility through April 28, 2025. Most significantly, on May 9, 2025, Abeona entered into an agreement to sell the Rare Pediatric Disease Priority Review Voucher (PRV) received upon ZEVASKYN approval for gross proceeds of $155.0 million (expected net proceeds of approximately $152 million). Management explicitly stated that these proceeds, combined with existing cash, provide sufficient financial resources to fund operations for over two years, extending the cash runway through the point of projected ZEVASKYN-driven profitability in early 2026. This robust financial footing is a critical de-risking factor for investors, eliminating the need for near-term dilutive financing to support the launch and reach profitability. The company's Loan Agreement terms were also favorably adjusted post-approval, with the start date for principal payments extended from May 1, 2025, to February 1, 2026, further easing near-term cash requirements.

The commercial launch of ZEVASKYN is now the primary focus. Management anticipates making the therapy available starting in the third quarter of 2025 through a network of Qualified Treatment Centers (QTCs). These are specialized EB centers with experience in cell and gene therapies. The activation of the first QTC, Lurie Children's Hospital of Chicago, ahead of schedule in May 2025, marks a significant step. Patient identification and scheduling can now begin, with the first patient treatment expected in Q3 2025, likely in August, following a biopsy in July and the approximately 25-day manufacturing process. Abeona plans to activate other geographically dispersed QTCs by the end of 2025. The launch is expected to see a gradual ramp-up at each center as they become familiar with the treatment process, patient journey, and reimbursement procedures. Management remains optimistic about achieving its 2025 goal of treating 10 to 14 patients, anticipating a robust start to 2026.

Manufacturing capacity is being strategically scaled to meet anticipated demand. The company's integrated cGMP facility in Cleveland provides control over the supply chain, a key operational strength for an autologous therapy. Initial capacity is approximately four treatments per month, with plans to ramp to six treatments per month starting late 2025/early 2026 and reaching a maximum of 10 monthly treatments in the first half of 2026 within the current facility. A long-term expansion plan is underway, with additional space leased and design work progressing, targeting capacity for over 200 annual treatments by the second half of 2027. Management expects the launch to be supply-gated initially, potentially leading to a patient backlog as demand builds.

Market access is a critical component of the launch strategy. Abeona is actively engaging with commercial payers and state Medicaid programs. The company has already executed outcomes-based agreements with two payer contracting organizations, signaling confidence in ZEVASKYN's value proposition and supporting favorable access. Plans include filing for the Medicaid Drug Rebate Application (MDRA) and applying for a ZEVASKYN-specific J-code to facilitate reimbursement. The company's patient support program, Abeona Assist, is designed to help patients navigate the complex treatment journey, including logistics and financial assistance.

Despite the significant progress and positive outlook, risks remain. As a newly commercial-stage company with its first product launch, assessing future viability is challenging. The success of ZEVASKYN's commercialization is paramount to overcoming historical operating losses and achieving profitability. Regulatory risks persist, including potential disruptions at the FDA or other agencies that could impact future approvals or ongoing compliance. Manufacturing and supply chain execution, while integrated, must meet the demands of scaling production for an autologous therapy. Competition, particularly from established players like Krystal Biotech, requires effective differentiation and market positioning. While the PRV sale provides a strong financial cushion, the ability to generate sufficient revenue from ZEVASKYN sales remains the ultimate determinant of long-term financial health and the ability to fund the ongoing pipeline development.

Conclusion

Abeona Therapeutics has reached a pivotal moment with the FDA approval and subsequent launch of ZEVASKYN, marking its transition to a commercial-stage company. The therapy's differentiated profile, offering durable healing for severe RDEB wounds with a single application, positions it to address a significant unmet need and complement existing treatments. Supported by a robust balance sheet following the $155 million PRV sale, Abeona is well-funded to execute its commercial strategy, which centers on activating specialized treatment centers and scaling its integrated manufacturing capacity.

While initial financial results reflect the necessary investments for launch, the path to profitability is now clearly defined, with management projecting positive EPS in 2026. The successful ramp-up of ZEVASKYN sales and effective market access will be critical to realizing this potential. As Abeona embarks on this new commercial era, its ability to leverage its technological strengths, navigate the competitive landscape, and execute its launch plan will determine its success and future growth trajectory, including the advancement of its promising ophthalmology pipeline.